An interleukin 6 responsive plasma cell signature is associated with disease progression in systemic sclerosis interstitial lung disease

Summary: Systemic sclerosis (SSc) interstitial lung disease (ILD) is among the leading causes of SSc-related morbidity and mortality. Tocilizumab (TCZ, anti-IL6RA) has demonstrated a reduced rate of pulmonary function decline in two phase 2/3 trials (faSScinate and focuSSced) in SSc-ILD patients. We...

Полное описание

Библиографические подробности

Главные авторы:	Guiquan Jia, Thirumalai R. Ramalingam, Jason Vander Heiden, Xia Gao, Daryle DePianto, Katrina B. Morshead, Zora Modrusan, Nandhini Ramamoorthi, Paul Wolters, Celia Lin, Dinesh Khanna, Joseph R. Arron
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2023-11-01
Серии:	iScience
Предметы:	Fibrosis Biological sciences Molecular biology Immunology
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2589004223022101
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!